Compare Booz Allen Hamilton Holding Corporation (BAH) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs BioNano Genomics Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.5 (market cap $9.45B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 691.8× BioNano Genomics Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BAH | BNGO | |
|---|---|---|
Market Cap | $9.45B | $13.66M |
Sector | Industrials | Health |
52-Week High | $111.63 | $4.92 |
52-Week Low | $59.71 | $1.06 |
Enterprise Value | $13.07B | $16.26M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $78.4, up 0.64% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 68.11% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights its focus on AI and cybersecurity, with a consensus analyst price target of $84.67 suggesting upside potential. Cash flow from operations improved to $1.01 billion in 2025.
The outlook is supported by national security demand and margin expansion, but risks include civil revenue weakness and high leverage. Valuation appears reasonable with a P/E of 12.33. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock offers a dividend yield from recent payouts.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
